<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p3" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_3{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_3{left:341px;bottom:30px;}
#t3_3{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_3{left:377px;bottom:30px;}
#t5_3{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_3{left:540px;bottom:30px;}
#t7_3{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_3{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_3{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_3{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_3{left:285px;bottom:827px;letter-spacing:-0.32px;word-spacing:-0.15px;}
#tc_3{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_3{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_3{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_3{left:1120px;bottom:47px;letter-spacing:0.09px;}
#tg_3{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_3{left:432px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#ti_3{left:759px;bottom:786px;letter-spacing:-0.12px;}
#tj_3{left:35px;bottom:383px;}
#tk_3{left:45px;bottom:377px;letter-spacing:0.08px;word-spacing:-0.01px;}
#tl_3{left:376px;bottom:377px;letter-spacing:0.12px;}
#tm_3{left:406px;bottom:377px;letter-spacing:0.13px;}
#tn_3{left:480px;bottom:377px;}
#to_3{left:35px;bottom:366px;}
#tp_3{left:45px;bottom:360px;letter-spacing:0.12px;}
#tq_3{left:44px;bottom:344px;letter-spacing:0.12px;}
#tr_3{left:44px;bottom:327px;letter-spacing:0.12px;}
#ts_3{left:44px;bottom:310px;letter-spacing:0.12px;}
#tt_3{left:44px;bottom:293px;letter-spacing:0.12px;}
#tu_3{left:44px;bottom:276px;letter-spacing:0.12px;}
#tv_3{left:44px;bottom:260px;letter-spacing:0.11px;word-spacing:0.02px;}
#tw_3{left:44px;bottom:243px;letter-spacing:0.12px;}
#tx_3{left:44px;bottom:226px;letter-spacing:0.12px;}
#ty_3{left:44px;bottom:209px;letter-spacing:0.09px;word-spacing:0.03px;}
#tz_3{left:44px;bottom:192px;letter-spacing:0.12px;}
#t10_3{left:190px;bottom:192px;letter-spacing:0.08px;word-spacing:-0.01px;}
#t11_3{left:507px;bottom:192px;letter-spacing:0.12px;}
#t12_3{left:44px;bottom:176px;letter-spacing:0.11px;word-spacing:0.01px;}
#t13_3{left:44px;bottom:159px;letter-spacing:0.13px;}
#t14_3{left:44px;bottom:142px;letter-spacing:0.08px;word-spacing:-0.02px;}
#t15_3{left:44px;bottom:125px;letter-spacing:0.12px;}
#t16_3{left:44px;bottom:108px;letter-spacing:0.02px;word-spacing:0.11px;}
#t17_3{left:672px;bottom:400px;}
#t18_3{left:682px;bottom:394px;letter-spacing:0.13px;word-spacing:-0.04px;}
#t19_3{left:681px;bottom:377px;letter-spacing:0.03px;}
#t1a_3{left:745px;bottom:377px;}
#t1b_3{left:672px;bottom:366px;}
#t1c_3{left:682px;bottom:360px;letter-spacing:0.11px;word-spacing:0.02px;}
#t1d_3{left:681px;bottom:344px;letter-spacing:0.12px;word-spacing:0.01px;}
#t1e_3{left:672px;bottom:333px;}
#t1f_3{left:682px;bottom:327px;letter-spacing:0.1px;word-spacing:0.02px;}
#t1g_3{left:681px;bottom:310px;letter-spacing:0.12px;}
#t1h_3{left:681px;bottom:293px;letter-spacing:0.11px;word-spacing:-0.06px;}
#t1i_3{left:681px;bottom:276px;letter-spacing:0.12px;}
#t1j_3{left:672px;bottom:266px;}
#t1k_3{left:682px;bottom:260px;letter-spacing:0.12px;}
#t1l_3{left:681px;bottom:243px;letter-spacing:0.13px;}
#t1m_3{left:681px;bottom:226px;letter-spacing:0.11px;word-spacing:0.02px;}
#t1n_3{left:672px;bottom:215px;letter-spacing:0.08px;}
#t1o_3{left:689px;bottom:209px;letter-spacing:0.09px;word-spacing:-0.09px;}
#t1p_3{left:681px;bottom:192px;letter-spacing:0.13px;}
#t1q_3{left:681px;bottom:176px;letter-spacing:0.13px;}
#t1r_3{left:672px;bottom:165px;letter-spacing:-0.83px;}
#t1s_3{left:688px;bottom:159px;letter-spacing:0.08px;word-spacing:0.01px;}
#t1t_3{left:681px;bottom:142px;letter-spacing:0.11px;word-spacing:-0.08px;}
#t1u_3{left:681px;bottom:125px;letter-spacing:0.12px;}
#t1v_3{left:681px;bottom:108px;letter-spacing:0.12px;word-spacing:0.01px;}
#t1w_3{left:36px;bottom:754px;letter-spacing:-0.1px;}
#t1x_3{left:36px;bottom:738px;letter-spacing:-0.11px;word-spacing:-0.62px;}
#t1y_3{left:36px;bottom:723px;letter-spacing:-0.1px;}
#t1z_3{left:41px;bottom:708px;}
#t20_3{left:58px;bottom:708px;letter-spacing:-0.09px;}
#t21_3{left:58px;bottom:693px;letter-spacing:-0.09px;}
#t22_3{left:58px;bottom:677px;letter-spacing:-0.09px;}
#t23_3{left:63px;bottom:662px;}
#t24_3{left:76px;bottom:662px;letter-spacing:-0.09px;}
#t25_3{left:77px;bottom:647px;letter-spacing:-0.26px;word-spacing:0.01px;}
#t26_3{left:580px;bottom:654px;}
#t27_3{left:77px;bottom:631px;letter-spacing:-0.16px;word-spacing:0.01px;}
#t28_3{left:92px;bottom:616px;letter-spacing:-0.09px;word-spacing:0.01px;}
#t29_3{left:103px;bottom:601px;letter-spacing:-0.09px;}
#t2a_3{left:92px;bottom:586px;}
#t2b_3{left:103px;bottom:586px;letter-spacing:-0.09px;}
#t2c_3{left:77px;bottom:570px;letter-spacing:-0.09px;word-spacing:-0.07px;}
#t2d_3{left:91px;bottom:555px;letter-spacing:-0.09px;}
#t2e_3{left:77px;bottom:540px;}
#t2f_3{left:91px;bottom:540px;letter-spacing:-0.09px;}
#t2g_3{left:91px;bottom:525px;letter-spacing:-0.1px;}
#t2h_3{left:41px;bottom:509px;}
#t2i_3{left:58px;bottom:509px;letter-spacing:-0.09px;}
#t2j_3{left:63px;bottom:494px;}
#t2k_3{left:76px;bottom:494px;letter-spacing:-0.09px;}
#t2l_3{left:547px;bottom:501px;}
#t2m_3{left:36px;bottom:470px;letter-spacing:-0.1px;}
#t2n_3{left:614px;bottom:754px;letter-spacing:-0.24px;}
#t2o_3{left:614px;bottom:737px;letter-spacing:-0.1px;}
#t2p_3{left:929px;bottom:744px;letter-spacing:-0.27px;}
#t2q_3{left:614px;bottom:720px;letter-spacing:-0.09px;}
#t2r_3{left:625px;bottom:703px;letter-spacing:-0.1px;}
#t2s_3{left:614px;bottom:686px;letter-spacing:-0.08px;}
#t2t_3{left:620px;bottom:670px;}
#t2u_3{left:636px;bottom:670px;letter-spacing:-0.09px;word-spacing:-0.08px;}
#t2v_3{left:636px;bottom:653px;letter-spacing:-0.09px;}
#t2w_3{left:786px;bottom:653px;letter-spacing:-0.35px;}
#t2x_3{left:835px;bottom:653px;}
#t2y_3{left:642px;bottom:636px;}
#t2z_3{left:655px;bottom:636px;letter-spacing:-0.09px;}
#t30_3{left:620px;bottom:619px;}
#t31_3{left:636px;bottom:619px;letter-spacing:-0.09px;}
#t32_3{left:642px;bottom:602px;}
#t33_3{left:655px;bottom:602px;letter-spacing:-0.09px;}
#t34_3{left:1125px;bottom:610px;}
#t35_3{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_3{font-size:9px;font-family:ArialMT_4v;color:#000;}
.s1_3{font-size:5px;font-family:ArialMT_4v;color:#000;}
.s2_3{font-size:12px;font-family:Arial-BoldMT_4z;color:#000;}
.s3_3{font-size:28px;font-family:Arial-BoldMT_4z;color:#000;}
.s4_3{font-size:17px;font-family:ArialMT_4v;color:#0065A4;}
.s5_3{font-size:17px;font-family:Arial-BoldMT_4z;color:#000;}
.s6_3{font-size:14px;font-family:Arial-BoldMT_4z;color:#000;}
.s7_3{font-size:12px;font-family:ArialMT_4v;color:#000;}
.s8_3{font-size:15px;font-family:ArialMT_4v;color:#0065A4;}
.s9_3{font-size:15px;font-family:ArialMT_4v;color:#000;}
.sa_3{font-size:15px;font-family:ArialMT_56;color:#000;}
.sb_3{font-size:17px;font-family:Webdings_5e;color:#000;}
.sc_3{font-size:17px;font-family:Arial-BoldMT_5m;color:#000;}
.sd_3{font-size:17px;font-family:SymbolMT_5u;color:#000;}
.se_3{font-size:17px;font-family:Arial-BoldMT_4z;color:#0065A4;}
.sf_3{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts3" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_4z;
	src: url("fonts/Arial-BoldMT_4z.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5m;
	src: url("fonts/Arial-BoldMT_5m.woff") format("woff");
}

@font-face {
	font-family: ArialMT_4v;
	src: url("fonts/ArialMT_4v.woff") format("woff");
}

@font-face {
	font-family: ArialMT_56;
	src: url("fonts/ArialMT_56.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_5u;
	src: url("fonts/SymbolMT_5u.woff") format("woff");
}

@font-face {
	font-family: Webdings_5e;
	src: url("fonts/Webdings_5e.woff") format("woff");
}

</style>
<div id="pg3Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg3" style="-webkit-user-select: none;"><object width="1210" height="935" data="3/3.svg" type="image/svg+xml" id="pdf3" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_3" class="t s0_3">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_3" class="t s1_3">® </span>
<span id="t3_3" class="t s0_3">(NCCN </span>
<span id="t4_3" class="t s1_3">® </span>
<span id="t5_3" class="t s0_3">), All rights reserved. NCCN Guidelines </span>
<span id="t6_3" class="t s1_3">® </span>
<span id="t7_3" class="t s0_3">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_3" class="t s2_3">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_3" class="t s2_3">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_3" class="t s3_3">NCCN Guidelines Version 4.2024 </span>
<span id="tb_3" class="t s3_3">Very Advanced Head and Neck Cancer </span>
<span id="tc_3" class="t s4_3">NCCN Guidelines Index </span>
<span id="td_3" class="t s4_3">Table of Contents </span>
<span id="te_3" class="t s4_3">Discussion </span>
<span id="tf_3" class="t s5_3">ADV-A </span>
<span id="tg_3" class="t s5_3">2 OF 2 </span>
<span id="th_3" class="t s5_3">PRINCIPLES OF RADIATION THERAPY </span>
<span id="ti_3" class="t s6_3">1,2 </span>
<span id="tj_3" class="t s7_3">1 </span>
<span id="tk_3" class="t s8_3">See Principles of Radiation Techniques (RAD-A) </span><span id="tl_3" class="t s9_3">and </span><span id="tm_3" class="t s8_3">Discussion</span><span id="tn_3" class="t s9_3">. </span>
<span id="to_3" class="t s7_3">2 </span>
<span id="tp_3" class="t s9_3">In general, the reirradiated population of patients with head and neck cancer described </span>
<span id="tq_3" class="t s9_3">in current literature represents a diverse but highly selected group of patients treated in </span>
<span id="tr_3" class="t s9_3">centers where there is a high level of expertise and systems in place for managing acute </span>
<span id="ts_3" class="t s9_3">and long-term toxicities. When the goal of treatment is curative and surgery is not an option, </span>
<span id="tt_3" class="t s9_3">reirradiation strategies can be considered for patients who: develop locoregional failures </span>
<span id="tu_3" class="t sa_3">or second primaries at ≥6 months after the initial radiotherapy; can receive additional </span>
<span id="tv_3" class="t s9_3">doses of radiotherapy of at least 60 Gy; and can tolerate concurrent chemotherapy. OARs </span>
<span id="tw_3" class="t sa_3">for toxicity should be carefully analyzed through review of dose-volume histograms, and </span>
<span id="tx_3" class="t s9_3">consideration for acceptable doses should be made on the basis of time interval since </span>
<span id="ty_3" class="t s9_3">original radiotherapy, anticipated volumes to be included, and patient's life expectancy. For </span>
<span id="tz_3" class="t s9_3">reirradiation dosing, s</span><span id="t10_3" class="t s8_3">ee Principles of Radiation Techniques (RAD-A)</span><span id="t11_3" class="t s9_3">. Proton therapy can </span>
<span id="t12_3" class="t s9_3">be considered when normal tissue constraints cannot be met by photon-based therapy, or </span>
<span id="t13_3" class="t s9_3">when photon-based therapy causes compromise of standard radiation dosing to tumor or </span>
<span id="t14_3" class="t s9_3">postoperative volumes (Takiar V, Garden AS, Ma D, et al. Reirradiation of head and neck </span>
<span id="t15_3" class="t s9_3">cancers with intensity modulated radiation therapy: Outcomes and analyses. Int J Radiat </span>
<span id="t16_3" class="t s9_3">Oncol Biol Phys 2016;95:1117-1131). </span>
<span id="t17_3" class="t s7_3">3 </span>
<span id="t18_3" class="t s8_3">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers </span>
<span id="t19_3" class="t s8_3">(SYST-A)</span><span id="t1a_3" class="t s9_3">. </span>
<span id="t1b_3" class="t s7_3">4 </span>
<span id="t1c_3" class="t s9_3">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 </span>
<span id="t1d_3" class="t s9_3">Gy with IMRT dose painting technique (dependent on dose per fraction). </span>
<span id="t1e_3" class="t s7_3">8 </span>
<span id="t1f_3" class="t s9_3">For doses &gt;70 Gy, some clinicians feel that the fractionation should be </span>
<span id="t1g_3" class="t s9_3">slightly modified (eg, &lt;2.0 Gy/fraction for at least some of the treatment) </span>
<span id="t1h_3" class="t sa_3">to minimize toxicity. An additional 2–3 doses can be added depending on </span>
<span id="t1i_3" class="t s9_3">clinical circumstances. </span>
<span id="t1j_3" class="t s7_3">9 </span>
<span id="t1k_3" class="t sa_3">Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with </span>
<span id="t1l_3" class="t s9_3">or without concomitant chemotherapy for locally advanced head and </span>
<span id="t1m_3" class="t s9_3">neck cancer. N Engl J Med 2004;350:1945-1952. </span>
<span id="t1n_3" class="t s7_3">10 </span>
<span id="t1o_3" class="t s9_3">Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent </span>
<span id="t1p_3" class="t s9_3">radiotherapy and chemotherapy for high-risk squamous-cell carcinoma </span>
<span id="t1q_3" class="t s9_3">of the head and neck. N Engl J Med 2004;350:1937-1944. </span>
<span id="t1r_3" class="t s7_3">11 </span>
<span id="t1s_3" class="t s9_3">Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally </span>
<span id="t1t_3" class="t s9_3">advanced head and neck cancers: A comparative analysis of concurrent </span>
<span id="t1u_3" class="t s9_3">postoperative radiation plus chemotherapy trials of the EORTC (#22931) </span>
<span id="t1v_3" class="t s9_3">and RTOG (#9501). Head Neck 2005;27:843-850. </span>
<span id="t1w_3" class="t s5_3">DEFINITIVE: </span>
<span id="t1x_3" class="t s5_3">RT Alone </span>
<span id="t1y_3" class="t s5_3">• PTV </span>
<span id="t1z_3" class="t sb_3"></span><span id="t20_3" class="t s5_3">High risk: Primary tumor and involved lymph nodes [this includes </span>
<span id="t21_3" class="t sc_3" data-mappings='[[29,"fi"]]'>possible local subclinical inﬁltration at the primary site and at the </span>
<span id="t22_3" class="t s5_3">high-risk level lymph node(s)] </span>
<span id="t23_3" class="t sd_3">◊ </span><span id="t24_3" class="t s5_3">Fractionation: </span>
<span id="t25_3" class="t s5_3">– 70–72 Gy (2.0 Gy/fraction) daily Monday–Friday in 7–7.5 weeks </span>
<span id="t26_3" class="t s6_3">8 </span>
<span id="t27_3" class="t s5_3">– Concomitant boost accelerated RT: </span>
<span id="t28_3" class="t sc_3" data-mappings='[[40,"fi"]]'>▪ 72 Gy/6 weeks (1.8 Gy/fraction, large ﬁeld; 1.5 Gy boost as </span>
<span id="t29_3" class="t s5_3">second daily fraction during last 12 treatment days) </span>
<span id="t2a_3" class="t sc_3">▪ </span><span id="t2b_3" class="t s5_3">66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </span>
<span id="t2c_3" class="t s5_3">– Hyperfractionation: 81.6 Gy/7 weeks </span>
<span id="t2d_3" class="t s5_3">(1.2 Gy/fraction, twice daily) </span>
<span id="t2e_3" class="t s5_3">– </span><span id="t2f_3" class="t sc_3" data-mappings='[[4,"fi"]]'>Modiﬁed fractionation: total dose &gt;70 Gy and treatment </span>
<span id="t2g_3" class="t s5_3">course &lt;7 weeks </span>
<span id="t2h_3" class="t sb_3"></span><span id="t2i_3" class="t s5_3">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t2j_3" class="t sd_3">◊ </span><span id="t2k_3" class="t s5_3">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t2l_3" class="t s6_3">4 </span>
<span id="t2m_3" class="t s5_3">Either IMRT (preferred) or 3D-CRT is recommended. </span>
<span id="t2n_3" class="t s5_3">POSTOPERATIVE: </span>
<span id="t2o_3" class="t s5_3">RT or Concurrent Systemic Therapy/RT </span>
<span id="t2p_3" class="t s6_3">3,9-11 </span>
<span id="t2q_3" class="t s5_3">• Preferred interval between resection and postoperative RT is </span>
<span id="t2r_3" class="t sc_3">≤6 weeks. </span>
<span id="t2s_3" class="t s5_3">• PTV </span>
<span id="t2t_3" class="t sb_3"></span><span id="t2u_3" class="t s5_3">High risk: Adverse pathologic features such as positive margins </span>
<span id="t2v_3" class="t s5_3">(see footnote g on </span><span id="t2w_3" class="t se_3">ADV-3</span><span id="t2x_3" class="t s5_3">) </span>
<span id="t2y_3" class="t sd_3">◊ </span><span id="t2z_3" class="t s5_3">60–66 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–6.5 weeks </span>
<span id="t30_3" class="t sb_3"></span><span id="t31_3" class="t s5_3">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t32_3" class="t sd_3">◊ </span><span id="t33_3" class="t s5_3">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t34_3" class="t s6_3">4 </span>
<span id="t35_3" class="t sf_3">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
